This federal contract award, valued at $12,737.42, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 50 MG tablets, a medication used to treat overactive bladder. The award has an ultimate completion date of October 25, 2024 and is structured as a firm fixed-price delivery order. This contract does not have a set-aside designation, indicating...
This federal contract award, valued at $7,382.47, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of Myrbetriq ER 50 mg tablets, a medication used to treat overactive bladder. The contract is a firm fixed-price delivery order with an ultimate completion date of April 23, 2025. It is not designated as a set-aside contract, indicating open competition....
This federal contract award, valued at $2,582.21, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The award is for the delivery of Myrbetriq ER 25 mg tablets, a medication used to treat overactive bladder. The contract is a firm fixed-price delivery order with an ultimate completion date of April 16, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award, valued at $18,474.64, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 50 mg tablets, a medication used to treat overactive bladder. This is a firm fixed-price delivery order contract with a completion date of July 1, 2024. The contract does not have a set-aside designation, indicating open competition....
This federal contract award, valued at $44,613.73, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 50 mg tablets, a medication used to treat overactive bladder. This is a firm fixed-price delivery order contract with a completion date of January 3, 2025. The contract does not have a set-aside designation, indicating open competition....
This federal contract award, valued at $3,275.08, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Myrbetriq ER 50 mg tablets, a medication used for the treatment of overactive bladder. The contract has an ultimate completion date of September 26, 2023 and is a delivery order with a firm fixed price pricing type. The contract award was not set aside for any specific business type....
This federal contract award, valued at $11,069.56, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 25 mg tablets, a medication used to treat overactive bladder. The contract has an ultimate completion date of March 7, 2025 and is structured as a Firm Fixed Price Delivery Order. It is not designated as a set-aside contract. AmerisourceBergen holds...
This federal contract award, valued at $2,321.88, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a Delivery Order contract for the supply of Myrbetriq ER 50 mg tablets, a medication used for the treatment of overactive bladder. The contract has a period of performance through January 17, 2025 and is a Firm Fixed Price arrangement. This award is part of a larger Indefinite Delivery...
This federal contract award, valued at $98,418.12, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 50 mg tablets, a medication used to treat overactive bladder. This award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA, valued at up to...
This federal contract award, valued at $27,760.73, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 50 mg tablets, a medication used to treat overactive bladder. The contract is a Firm Fixed Price Delivery Order with a completion date of July 18, 2024. It is not associated with a set-aside designation, indicating open competition....